Journal of Managed Care + Specialty Pharmacy (JMCP)Costs of Obesity, Obesity-related Complications, and Weight Loss in the United States: A Systematic Literature Review

This systematic literature review analyzed 32 studies examining direct medical costs among people with obesity in the United States, finding costs increase substantially with obesity severity and complications. The review provides critical economic data for pharmacists evaluating obesity medication value propositions and supporting formulary decisions.

⚕️ Key Clinical Considerations ⚕️

• Cost escalation by severity: Direct medical costs range from 1.1-fold (Class I) to 3.3-fold (Class III) higher than normal weight populations
• Complication burden impact: Costs increase up to 5-fold with type 2 diabetes and hypertension, reaching 7-fold with multiple complications
• Weight loss benefit threshold: Even 5% weight loss demonstrates substantial cost savings within one year across all obesity classes
• Medication evidence gaps: Limited real-world cost data available for newer GLP-1 agonists like semaglutide and tirzepatide
• Longitudinal cost trajectory: Annual costs increase progressively over time, with greatest acceleration in the year following obesity diagnosis

🎯 Clinical Practice Impact 🎯

• Patient Communication: Use cost data to demonstrate economic value of weight management interventions and medication adherence to patients and payers.
• Practice Integration: Incorporate obesity severity classification and complication assessment into medication therapy management protocols to prioritize high-risk patients.
• Risk Management: Document obesity-related complications systematically to support prior authorization requests and demonstrate medical necessity for expensive obesity medications.
• Action Items: Develop cost-effectiveness arguments for formulary committees highlighting potential savings from preventing diabetes and cardiovascular complications.
• Formulary Strategy: Advocate for broader obesity medication coverage by presenting long-term cost offset data to pharmacy benefit managers and health plans.

More in Obesity & Weight Management